Abstract: Provided herein are compositions and methods for detection of N6-methyladenosine (m6A) in ribonucleic acid (RNA). The provided compositions include fusion proteins that can be used to edit RNA and detect m6A residues. Also provided are nucleic acids, vectors, constructs, host cells, and transgenic animals that encode or express such fusions proteins.

Abstract: Described herein are methods, compositions, and kits for treating and/or preventing in a subject one or more side effects associated with radiation and/or chemotherapy exposure, including methods, compositions and kits that include an active agent at a low dose. In some embodiments, methods, compositions, and kits for treating and/or preventing tissue damage in a subject are provided, including methods, compositions and kits that include an active agent at a low dose.

Abstract: The present disclosure provides genetically modified flowering plants that produce seedless fruit and methods for making and cultivating such plants. The genetically modified flowering plants express a modified Auxin Response Factor 8A (ARF8A) or an ortholog thereof.

Abstract: The disclosure provides compounds that inhibit the invasion of host cells by intracellular pathogens. The disclosure also relates to use of such compounds in methods of treating and preventing periodontitis or a periodontitis-related condition or symptom.

Abstract: The disclosure describes various aspects of a software-defined quantum computer. For example, a software-defined quantum computing architecture for allocating qubits is described that includes an application programming interface (API); a quantum operating system (OS) on which the API executes, with the quantum OS including a resource manager and a switch; and a plurality of quantum cores connected by the switch of the quantum resource OS. Moreover, the resource manager of the quantum resource OS determines an allocation of a plurality of qubits in the plurality of quantum cores.

Abstract: The present invention relates to novel synthetic odorant receptors capable of cell surface localization upon cellular expression. Specifically, the present invention provides synthetic odorant receptors having a consensus amino acid sequence deduced from a plurality of odorant receptors within an odorant receptor family, wherein the consensus amino acid sequence represents the mostly frequently present amino acid residues for each amino acid position deduced from a plurality of odorant receptors within an odorant receptor family. Additionally, the present invention provides methods of use, methods of synthesis, and cell lines expressing one or more of such novel synthetic odorant receptors.

Abstract: The present disclosure is directed to methods of treating a steatosis-associated disorder and methods of treating a cytoplasmic glycogen storage disorder, including glycogen storage disease I, glycogen storage disease III, glycogen storage disease IV, and/or conditions associated with a PRKAG2 mutation, by administering a therapeutic agent selected from a lysosomal enzyme, an autophagy-inducing agent, or a combination thereof. Steatosis-associated disorders discussed herein include GSD Ia, GSD Ib, GSD Ic, NAFLD, and NASH. Other embodiments are directed to methods of reversing steatosis, modulating autophagy, inducing autophagy, and reversing glycogen storage. Methods of treating a cytoplasmic glycogen storage disorder by administering a lysosomal enzyme and a second therapeutic agent are also described. Other embodiments are directed to methods of treating a cytoplasmic glycogen storage disorder by administering a therapeutic agent as an adjunctive therapy to lysosomal enzyme replacement therapy.

Abstract: Provided herein are compositions including a CaMKK2 inhibitor and an anti-cancer therapeutic agent and methods of treating cancer in a subject by administering a therapeutically effective amount of the composition to a subject. The subject may be selected for treatment based on an immune cell measurement of a sample from the subject. Methods of treating cancer by administering a therapeutically effective amount of a CaMKK2 inhibitor, and administering a therapeutically effective amount of an anti-cancer therapeutic agent to the subject are also provided. Kits including combination of a CaMKK2 inhibitor and another anti-cancer therapeutic agent are also provided.

Abstract: The disclosure describes various aspects of a software-defined quantum computer. For example, a method is described for generating an intermediate representation of source code for a software-defined quantum computer. The method includes performing a lexical analysis on a high-level intermediate representation of a quantum programming language; performing semantic analysis on an output of the lexical analysis; and generating a mid-level intermediate representation of the quantum programming language based on an output of the semantic analysis.

Abstract: Technologies for performing error correction in a quantum circuit of a quantum computing system are disclosed. A quantum error correction code (QECC) is selected. The QECC is associated with a codespace. The quantum computing system identifies, based on one or more properties of the QECC, one or more diagonal physical gates in the quantum circuit that induces a target logical gate and preserves the codespace. The quantum computing system configures the quantum computing circuit to implement a quantum error correction protocol using the QECC and at least one of the identified diagonal physical gates.

Abstract: Described are oxysterols, pharmaceutical compositions including the oxysterols, and methods of using the oxysterols and compositions for treating diseases and/or disorders related to myelin injury, such as neonatal brain injury, traumatic brain injury, spinal cord injury, cerebral palsy, seizures, cognitive delay, multiple sclerosis, stroke, autism, leukodystrophy, schizophrenia and bipolar disorder.

Abstract: The present invention relates to the prevention or treatment of atherosclerosis, in particular to a B cell depleting agent for the prevention or treatment of atherosclerosis.

Abstract: A compressed gas energy storage system to provide isothermal compression/expansion for energy storage includes a housing defining an envelope including an internal volume; a phase change material (PCM) partially filling the internal volume; a dendritic (hierarchical) gas flow path through the PCM; and a piston driven by a drive mechanism and that moves relative to the PCM within the housing.

Abstract: This disclosure relates to methods of regulating growth in a plant. Specifically, the methods of the disclosure regulate growth of the plant by administration of a composition comprising an effective amount of one or more apocarotenoids to the plant, its part, or the seed.

Abstract: The present disclosure provides adeno-associated virus (AAV) vectors, comprising coevolved capsid variant proteins, pharmaceutical compositions, methods of making, and methods for delivering such to a subject.

Abstract: The present disclosure provides compositions comprising anti-LMP2 TCR-T cell populations for the treatment of EBV-associated cancers and methods of making and using same.

Abstract: A package-level, integrated high-vacuum ion-chip enclosure having improved thermal characteristics is disclosed. Enclosures in accordance with the present invention include first and second chambers that are located on opposite sides of a chip carrier, where the chambers are fluidically coupled via a conduit through the chip carrier. The ion trap is located in the first chamber and disposed on the chip carrier. A source for generating an atomic flux is located in the second chamber. The separation of the source and ion trap in different chambers affords thermal isolation between them, while the conduit between the chambers enables the ion trap to receive the atomic flux.

Abstract: The technology is directed to HIV envelopes which comprise sequence modifications wherein these modifications prevent CD4-induced transitions of the HIV envelope. Specifically, the disclosure provides recombinant HIV-1 Env proteins comprising mutations, wherein the envelope is a protomer, and wherein three protomers form a trimer stabilized by the presence of the mutations. Provided also are compositions comprising envelopes of the technology, and methods of use.

Abstract: The present disclosure provides methods and compositions for detecting and treating acute transplant rejection.

Abstract: The disclosure provides compounds that inhibit the invasion of host cells by intracellular parasites. These find use, for example, in treating and preventing periodontitis or a periodontitis-related condition or symptom.